The Hippo–YAP pathway has emerged as a central regulator of tissue growth and oncogenesis, yet remains resistant to conventional pharmacological targeting. Patent application WO 2026/044133 A1 discloses small-molecule strategies that modulate YAP activity through transcriptional complex disruption and protein stability interference. Robust cellular validation across YAP-dependent cancer models establishes proof of concept for tractable YAP inhibition, with implications spanning oncology and regenerative medicine.
Renner et al. (Tue,) studied this question.